Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

December 1, 2021

Study Completion Date

December 31, 2024

Conditions
COVID
Interventions
DIETARY_SUPPLEMENT

Omnibiotic AAD

Bacterial strains in Omni-Biotic® 10 AAD are Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W1, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 which are embedded in a matrix containing maize starch, maltodextrin, inulin, potassium chloride, hydrolysed rice protein, magnesium sulphate, fructooligosaccharide (FOS), enzymes (amylases), vanilla flavour and manganese sulphate

DIETARY_SUPPLEMENT

Placebo

matrix containing maize starch, maltodextrin, inulin, potassium chloride, hydrolysed rice protein, magnesium sulphate, fructooligosaccharide (FOS), enzymes (amylases), vanilla flavour and manganese sulphate.

Trial Locations (1)

8010

Department of Internal Medicine, Medical University of Graz, Graz

All Listed Sponsors
lead

Medical University of Graz

OTHER

NCT04420676 - Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection | Biotech Hunter | Biotech Hunter